Abstract
Target-based screening and cell-based screening are major approaches to identify anticancer drug candidates. Cell-based screening often contributes to the discovery of first-in-class drugs, but identification of the cellular targets of obtained compounds is a time-consuming step. To overcome this problem, affinity purification with small-molecule probes, which is a classic, but still the most common approach, has become more sophisticated and diversified. In addition, recent advances in omics studies and imaging analyses have allowed us to profile the biological effects of small molecules globally and quantitatively. Consequently, new therapeutic targets/drug leads involved in cancer cell cycle, transcription and redox regulation have been discovered.
MeSH terms
-
Aminoquinolines / pharmacology
-
Aminoquinolines / therapeutic use
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / therapeutic use
-
Carbamates / pharmacology
-
Carbamates / therapeutic use
-
Cell Cycle / drug effects
-
Cell Cycle / genetics
-
Coumarins / pharmacology
-
Coumarins / therapeutic use
-
Diamines / pharmacology
-
Diamines / therapeutic use
-
Diterpenes, Kaurane / pharmacology
-
Diterpenes, Kaurane / therapeutic use
-
Drug Discovery*
-
Humans
-
Molecular Targeted Therapy*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics*
-
Neoplasms / pathology
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use
-
Quinolines / pharmacology
-
Quinolines / therapeutic use
Substances
-
Aminoquinolines
-
Antineoplastic Agents
-
BNS 22
-
Carbamates
-
Coumarins
-
Diamines
-
Diterpenes, Kaurane
-
Pyrazoles
-
Quinolines
-
SCH 51344
-
adenanthin
-
apcin